Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by iA Global Asset Management Inc.

iA Global Asset Management Inc. raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 20,248 shares of the biopharmaceutical company’s stock after purchasing an additional 1,008 shares during the period. iA Global Asset Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $11,385,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC increased its stake in shares of Regeneron Pharmaceuticals by 261.8% during the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after purchasing an additional 686 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in shares of Regeneron Pharmaceuticals in the first quarter valued at approximately $226,000. CX Institutional increased its position in shares of Regeneron Pharmaceuticals by 7.9% during the second quarter. CX Institutional now owns 302 shares of the biopharmaceutical company’s stock worth $159,000 after purchasing an additional 22 shares in the last quarter. Sowell Financial Services LLC raised its stake in Regeneron Pharmaceuticals by 4.7% in the 2nd quarter. Sowell Financial Services LLC now owns 583 shares of the biopharmaceutical company’s stock valued at $306,000 after purchasing an additional 26 shares during the last quarter. Finally, U.S. Capital Wealth Advisors LLC boosted its stake in Regeneron Pharmaceuticals by 10.9% during the 2nd quarter. U.S. Capital Wealth Advisors LLC now owns 459 shares of the biopharmaceutical company’s stock worth $241,000 after purchasing an additional 45 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

REGN has been the topic of several research reports. Morgan Stanley raised their price target on shares of Regeneron Pharmaceuticals from $767.00 to $768.00 and gave the stock an “equal weight” rating in a research note on Friday, December 12th. Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, December 29th. Bank of America upgraded Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and upped their price target for the company from $627.00 to $860.00 in a research report on Wednesday, January 7th. Truist Financial lifted their price objective on Regeneron Pharmaceuticals from $798.00 to $820.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Finally, Wall Street Zen upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, January 10th. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $794.70.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 1,500 shares of the business’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the sale, the director directly owned 1,703 shares in the company, valued at $1,362,400. This represents a 46.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Jason Pitofsky sold 431 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the transaction, the vice president owned 4,233 shares of the company’s stock, valued at $2,757,503.19. This trade represents a 9.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 8,431 shares of company stock valued at $5,733,521 in the last three months. 7.02% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $755.51 on Friday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $821.11. The business has a fifty day moving average of $754.18 and a two-hundred day moving average of $641.57. The stock has a market cap of $79.40 billion, a price-to-earnings ratio of 18.09, a price-to-earnings-growth ratio of 1.95 and a beta of 0.39. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. The firm had revenue of $3.75 billion during the quarter, compared to the consensus estimate of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The company’s quarterly revenue was up .9% on a year-over-year basis. During the same period last year, the company earned $12.46 EPS. As a group, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, December 5th. Investors of record on Thursday, November 20th were issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date was Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.43%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.